<DOC>
	<DOCNO>NCT02629848</DOCNO>
	<brief_summary>This study evaluate progression free survival ( PFS ) , overall survival ( OS ) , objective response rate ( ORR ) , duration response , safety motesanib ( AMG706 ) combination paclitaxel carboplatin compare placebo combination paclitaxel carboplatin .</brief_summary>
	<brief_title>Study Motesanib ( AMG 706 ) Combination With Paclitaxel Carboplatin Advanced Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The drug test study call motesanib . Motesanib test combination paclitaxel carboplatin treat people Stage IV recurrent non-squamous non-small cell lung cancer ( NSCLC ) . This study look progression free survival , overall survival , overall response safety . The study enrol 401 patient . Participants randomly assign ( chance , like flip coin ) one two treatment groups—which remain undisclosed patient study doctor study ( unless urgent medical need ) : - Motesanib 125 mg + Paclitaxel + Carboplatin - Placebo ( dummy inactive pill ) - tablet look like study drug active ingredient + Paclitaxel + Carboplatin All participant ask take 5 X 25 mg motesanib tablet placebo time day throughout study . All participant receive treatment paclitaxel 200 mg/m^2 intravenous ( IV ) carboplatin IV Day 1 3 week Cycle 6 Cycles . After 6 Cycles participant could continue receive motesanib placebo alone 36 month . This multi-centre trial conduct worldwide . The overall time participate study 36 month . Participants make multiple visit clinic , plus final visit 30 day receive last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Disease Related : 1 . Histologically cytologically confirm , Stage IV recurrent nonsquamous nonsmall cell lung cancer ( NSCLC ) ( except diagnosis sputum cytology ) . Adenosquamous histology unclear histology subtype contain 10 % squamous cell allow . 2 . No prior chemotherapy , molecularlytargeted therapy , immunotherapy . Neoadjuvant postoperative adjuvant therapy except chemotherapy platinum agent complete 1 year prior randomization permit . 3 . Measurable nonmeasurable lesion per Response Evaluation Criteria Solid Tumor ( RECIST ) Version 1.1 criterion ( except nonmeasurable lesion malignant effusion ) . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . 5 . Life expectancy ≥ 3 month document Investigator . Demographic : Must 18 year age old time inform consent obtain . Laboratory : 1 . Hematological function , follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L . Platelet count ≥ 100 x 10^9/L ≤ 850 x 10^9/L . Hemoglobin ≥ 9 g/dL . 2 . Renal function , follow : Creatinine clearance ( GFR ) &gt; 40 mL/min ( calculate CockcroftGault formula ) . Urinary protein quantitative value ≤ 30 mg urinalysis ≤ 1+ dipstick unless total quantitative protein &lt; 500 mg 24hour urine sample . 3 . Hepatic function , follow : Aspartate aminotransferase ( AST ) ≤ 2.5 x upper limit normal ( ULN ) AST &lt; 5 x ULN liver metastases present . Alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ALT &lt; 5 x ULN liver metastases present . Alkaline phosphatase ( ALP ) ≤ 2.0 x ULN ALP &lt; 5 x ULN liver bone metastasis present . Total bilirubin &lt; 1.5 x ULN . 4 . Coagulation function , follow : Partial thromboplastin time ( PTT ) activate partial thromboplastin time ( aPTT ) ≤ 1 x ULN . International normalized ratio ( INR ) ≤ 1.5 x ULN . Ethical : Ability give write informed consent . General : 1 . Able take oral medication . 2 . Able start protocoldirected therapy within 7 day date randomization . Disease Related : 1 . Symptomatic central nervous system metastasis . Participants asymptomatic brain metastasis eligible definitive therapy administer ( surgery and/or radiation therapy ) , plan treatment brain metastasis , participant clinically stable corticosteroid least 2 week prior randomization . Participants asymptomatic brain metastasis also eligible participant need definitive therapy ( surgery and/or radiation therapy ) corticosteroid accord Investigator 's judgement . 2 . Palliative radiation therapy : Radiation therapy within 28 day prior randomization central ( chest ) . Radiation therapy within 14 day prior randomization distant metastatic focus . 3 . History pulmonary hemorrhage gross hemoptysis ( approximately 3 mL bright red blood ) within 6 month prior randomization . Medications : 1 . Prior targeted therapy , include limited : • AMG 706 , inhibitor vascular endothelial growth factor ( VEGF ) ( eg , SU5416 , SU6668 , ZD6474 , SU11248 , PTK787 , AZD2171 , AEE788 , sorafenib , bevacizumab ) , epidermal growth factor receptor ( EGFR ) ( eg , panitumumab , cetuximab , gefitinib , erlotinib ) . 2 . Any anticoagulation therapy within 7 day prior randomization . The use lowdose warfarin ( ≤ 2 mg daily ) low molecular weight heparin heparin flush prophylaxis central venous catheter thrombosis allow . 3 . Known history allergy hypersensitivity reaction paclitaxel carboplatin . General : 1 . History arterial venous thrombosis within 12 month prior randomization . 2 . History bleed diathesis bleeding within 14 day prior randomization . 3 . Peripheral neuropathy ≥ Grade 2 per Common Terminology Criteria Adverse Events ( CTCAE ) Version 3.0 . 4 . Clinically significant cardiovascular disease within 12 month randomization , include myocardial infarction , unstable angina , ≥ Grade 2 peripheral vascular disease , cerebrovascular accident , transient ischemic attack , percutaneous transluminal coronary angioplasty/stent , congestive heart failure ongoing arrhythmias require medication . 5 . Any kind disorder compromise ability participant comply study procedure . 6 . Open wound , ulcer fracture . 7 . Active uncontrolled , infection inflammatory disease require systemic treatment ≤ 14 day prior randomization . 8 . Diagnosed interstitial lung disease and/or significant interstitial shadow computerize tomography ( CT ) image . 9 . Uncontrolled hypertension define rest blood pressure &gt; 150/90 mmHg despite use antihypertensive . 10 . History ( past/current ) primary cancer unless : Curatively resect nonmelanomatous skin cancer . Curatively treated cervical carcinoma situ . Other primary solid tumor curatively treat know active disease present curative treatment administer last 3 year . 11 . Surgery : Major surgical procedure within 28 day prior randomization . Minor surgical procedure within 14 day prior randomization . Failure recover prior surgery . Placement central venous access device ( include port tunnel nontunneled catheter ) within 3 day principle prior randomization . Core needle biopsy within 7 day prior randomization . 12 . Planned elective surgery study treatment . 13 . Not recover previous therapy ( ie , radiation , surgery medication ) . AEs relate previous therapy must CTCAE Grade ≤ 1 Screening must resolve participant 's Baseline level prior recent previous therapy ( except alopecia ) . 14 . Participation therapeutic clinical trial currently receive investigational treatment ( ) within 30 day prior randomization . 15 . Pregnant ( eg , positive human chorionic gonadotropin [ HCG ] testurine serum ) breastfeed woman . 16 . Any participant consenting use adequate contraceptive precaution , inform consent 6 month last treatment . 17 . Known human immunodeficiency virus ( HIV ) , hepatitis B surface ( HBs ) antigen hepatitis C positive . Participants may HBs antigen ( ) HB core antibody ( + ) /or HBs antibody ( + ) hepatitis B virus ( HBV ) deoxyribonucleic acid ( DNA ) ( ) . If HBs antigen ( ) HBV DNA ( + ) , participant could enrol concomitant antiviral treatment ( entecavir tenofovir ) . In case hepatitis C virus ( HCV ) antibody ( + ) HCV ribonucleic acid ( ) and/or HCV core antigen ( ) , participant could enrol . Participant HBs antigen ( + ) could enrol AST ALT within ULN , HBV DNA level le 3.0 Log . The participant must receive concomitant antiviral treatment ( entecavir tenofovir ) . Participants already antiviral treatment Screening eligible . 18 . Known chronic hepatitis . 19 . History medical psychiatric condition laboratory abnormality , opinion Investigator , may increase risk associate participation study administration investigational product ( IPs ) administration , may interfere interpretation result . 20 . Previously randomize study . 21 . Not available followup assessment unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>